针对IGF2BPs的循环RNA在癌症中的作用 - - 这是癌症治疗的潜在目标
Xia Luo1, Jiaxin Shi1, Siyuan Wang1
1Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Health Science Center, Ningbo University, Ningbo, 315211, China.
概括
循环RNAs (circRNAs) 和胰岛素样生长因子-2 mRNA结合蛋白 (IGF2BPs) 是癌症的关键调节者. 本综述探讨了它们在瘤进展中的作用,机制和临床潜力.
科学领域:
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
背景情况:
- 循环RNAs (circRNAs) 是具有多种调节功能的RNA分子.
- 胰岛素样生长因子-2 mRNA结合蛋白 (IGF2BPs) 是RNA结合蛋白,对RNA处理和代谢至关重要.
- 无论是circRNAs还是IGF2BPs都与瘤进展有关.
研究的目的:
- 总结circRNAs和IGF2BPs在癌症发展中的作用和分子机制.
- 审查其他RNA和IGF2BPs在癌症中的参与.
- 讨论当前的临床应用和未来的方向.
主要方法:
- 在癌症中对circRNAs和IGF2BPs的文献综述.
- 对癌症进展中的分子机制的分析.
- 讨论临床应用和挑战.
主要成果:
- 循环RNAs作为microRNA海绵,拼接和转录的调节器,以及RNA结合蛋白海绵.
- IGF2BPs微调RNA稳定性,翻译和局部化,影响细胞功能和病理生理学.
- 这两种分子在癌症的发展和进展中都起着重要作用.
结论:
- 了解circRNA和IGF2BP的功能对于癌症研究至关重要.
- 对其临床应用的进一步研究对癌症治疗有希望.
- 应对当前的挑战将为未来的进步铺平道路.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


